Colitis Ulcerosa

News Colitis Ulcerosa

• Shield Signs Agreement for ST10-021 with AOP Orphan Pharmaceuticals

  Shield Holdings AG announced that it has signed a strategic commercialisation agreement for its lead asset, ST10-021, an iron therapy product which has commenced Phase III clinical development, with AOP Orphan Pharmaceuticals AG (“AOP”). Under the terms of the agreement, Shield, whose products ad more

• Reshaping the gut microbiome could herald new treatments for bowel diseases

  Home to a diverse range of microorganisms, a healthy human body contains at least tenfold more bacteria cells than human cells. The most abundant and diverse microbial community resides in the intestine, and changes to the gut microbiota are linked with diseases such as ulcerative colitis and Crohn more

• First step to new therapy for chronic bowel disease

  Scientists associated with VIB (Flanders Institute for Biotechnology) and Ghent University (UGent) have discovered that A20 protein plays an important protective role in diseases associated with chronic bowel inflammation. This makes A20 into a promising therapeutic target for the development of new more

Publications Colitis Ulcerosa

• Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease – an update

  Adhesion molecules play a key role in the pathogenetic mechanisms of inflammatory bowel disease (IBD), both in Crohn’s disease (CD) and ulcerative colitis (UC). In the last decade, some progress has been made in understanding their key role in leukocyte trafficking control in terms of basic research more

• Amelioration of Dextran Sulphate Sodium‐Induced Colitis in Mice by Echinacoside‐Enriched Extract of Cistanche tubulosa

  Echinacoside (ECH) is a major bioactive phenyethanoids in medicinal herba Cistanche and has been reported to have antiinflammatory activity and beneficial effect on wound healing in many experimental studies. This study was to test the efficacy of ECH‐enriched extract of Cistanche tubulosa in the more

• Loss of response to biologics versus increased risk of lymphoma in children with inflammatory bowel disease: the clinician’s conundrum

  Inflammatory bowel disease in children can be marked by aggressive disease both at presentation and over time. Risk stratification of individual patients may help identify when early biologic therapy is justified. Currently, combination biologic and immunomodulator therapy for moderate-to-severe Cro more

Market studies Colitis Ulcerosa

• Ulcerative Colitis – Pipeline Review, H2 2012

  Introduction Global Markets Direct’s, 'Ulcerative Colitis - Pipeline Review, H2 2012', provides an overview of the Ulcerative Colitis therapeutic pipeline. This report provides information on the therapeutic development for Ulcerative Colitis, complete with latest updates, and special features on more

• Ulcerative Colitis – Pipeline Review, H1 2012

  Introduction Global Markets Direct’s, 'Ulcerative Colitis - Pipeline Review, H1 2012', provides an overview of the Ulcerative Colitis therapeutic pipeline. This report provides information on the therapeutic development for Ulcerative Colitis, complete with latest updates, and special features on more

• Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments

  GBI Research, the leading business intelligence provider, has released its latest research “Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments”, which provides insights into more

Websites Colitis Ulcerosa